DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL - DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether a new drug called SCTB35, combined with standard chemotherapy, works better than the current standard treatment (rituximab plus chemo) for people whose diffuse large B-cell lymphoma has come back or stopped responding to prior therapy. About 101 adults ag…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a reshaped chemo combo tame lymphoma with fewer side effects?
Disease control Recruiting nowThis Phase 3 trial compares a modified version of the standard DHAP chemotherapy regimen against the original in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The modified regimen spreads out the cisplatin and cytarabine doses over several days, aiming…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: King Edward Medical University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Four-Pronged attack beat brain lymphoma?
Disease control Recruiting nowThis trial is testing whether combining a short course of focused radiation with three drugs—GM-CSF, pomalidomide, and glofitamab—can effectively treat newly diagnosed primary central nervous system diffuse large B-cell lymphoma (PCNSL), a rare and aggressive cancer of the brain …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Xiamen University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for hard-to-treat lymphoma: first human trial of LTZ-301 begins
Disease control Recruiting nowThis early-phase trial tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug cocktail aims to outsmart aggressive blood cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy, with or without a stem cell transplant, can improve outcomes for people newly diagnosed with an aggressive type of non-Hodgkin lymphoma called DLBCL. The study enrolls 30 adults aged…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Double punch: CAR-T cells followed by antibodies may boost lymphoma remission
Disease control Recruiting nowThis study tests whether giving additional antibody drugs (mosunetuzumab or glofitamab plus obinutuzumab) after CAR-T cell therapy can improve outcomes for people with relapsed or refractory large B-cell lymphoma. About 23 participants will receive the combination to see if it le…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for tough lymphomas: experimental drug MDX2003 enters human testing
Disease control Recruiting nowThis study tests an experimental drug called MDX2003 in 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cell therapy CT1182 takes on tough lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for tough lymphoma: glofitamab trial launches in china
Disease control Recruiting nowThis study tests a drug called glofitamab in 20 Chinese patients whose diffuse large B-cell lymphoma has returned or not responded to at least two prior treatments. The goal is to see if the drug can control the cancer and how safe it is. Participants receive glofitamab alone, an…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy aims to boost lymphoma remission in patients with key mutations
Disease control Recruiting nowThis study tests whether adding the oral drug zanubrutinib to standard chemotherapy (R-CHOP) can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL) who have certain genetic mutations (MYD88, CD79B, NOTCH1) or a specific marker (CD5+). About 21 adults will rece…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on tough lymphoma in new trial
Disease control Recruiting nowThis phase 2 trial tests a new CAR T cell therapy called MB-CART2019.1 in 31 people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, genetically modified to target and k…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Tuning up CAR t: can a better prep boost lymphoma remission?
Disease control Recruiting nowThis study is for adults with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to treatment. Researchers want to find the safest and most effective way to prepare the body before giving standard CAR T cell therapy. They are t…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New triple therapy hopes to tackle tough lymphoma
Disease control Recruiting nowThis study tests a combination of three drugs (pirtobrutinib, lisaftoclax, and rituximab) in adults with diffuse large B-cell lymphoma that has come back or not responded to at least one prior treatment. The goal is to see if this combination can shrink or eliminate tumors. About…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Heart shield for lymphoma patients: new trial aims to stop Chemo-Induced heart failure
Prevention Recruiting nowThis study tests whether the drug dexrazoxane can prevent heart damage caused by chemotherapy in people with diffuse large B-cell lymphoma (DLBCL). About 324 patients will receive either standard treatment plus dexrazoxane or standard treatment alone. The goal is to see if dexraz…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Prevention
Last updated Jun 27, 2026 08:09 UTC
-
New spinal fluid test could spot hidden lymphoma in the brain
Knowledge-focused Recruiting nowThis study is testing a new spinal fluid test that looks for tumor DNA in people with aggressive B-cell lymphoma who are at high risk for the cancer spreading to the brain. Researchers want to see how often this test finds signs of lymphoma that standard tests miss. About 50 part…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Can a simple training improve tough cancer conversations?
Knowledge-focused Recruiting nowThis study is testing a new communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors better discuss the diagnosis and plan future care with their patients. About 48 people (doctors and patients) will take part to…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC